Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Accolade, Inc.
  6. Summary
    ACCD   US00437E1029

ACCOLADE, INC.

(ACCD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
47.24(c) 46.72(c) 45.61(c) 44.99(c) 45.41 Last
409 982 439 084 648 343 816 220 3 652 142 Volume
+0.13% -1.10% -2.38% -1.36% +0.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 303 M - -
Net income 2022 -134 M - -
Net cash position 2022 147 M - -
P/E ratio 2022 -22,0x
Yield 2022 -
Sales 2023 395 M - -
Net income 2023 -110 M - -
Net cash position 2023 96,9 M - -
P/E ratio 2023 -28,0x
Yield 2023 -
Capitalization 3 000 M 3 000 M -
EV / Sales 2022 9,41x
EV / Sales 2023 7,35x
Nbr of Employees 1 900
Free-Float 94,2%
More Financials
Company
Accolade Inc. is a provider of personalized, technology-enabled solutions that helps people to understand, navigate, and utilize the healthcare system and their workplace benefits. The Company’s customers are primarily employers that deploy Accolade in order to provide employees and their families members a single place to turn for their health, healthcare, and benefits needs. Its platform combines open,... 
More about the company
Ratings of Accolade, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ACCOLADE, INC.
08:38aACCOLADE : Baird Upgrades Accolade to Outperform from Neutral, Adjusts Price Tar..
MT
07:55aACCOLADE : Baird Upgrades Accolade to Outperform From Neutral, Trims Price Targe..
MT
09/16ACCOLADE : to Announce Fiscal Second Quarter 2022 Financial Results
AQ
09/07ACCOLADE : How Accolade bends the healthcare cost curve
PU
09/07Accolade to Participate in Upcoming Investor Conferences
GL
08/26ACCOLADE : Save your HR team time and bandwidth
PU
08/23SUPPORTING EMPLOYEE MENTAL HEALTH : Advice from Dr. Brian Wong
PU
08/17ACCOLADE : Virtual care won't replace office traditional care – but will s..
PU
08/11ACCOLADE : 5 tips on how to talk to your CFO about healthcare advocacy
PU
08/10ACCOLADE : Supporting mental health wellness during times of change
PU
08/10ACCOLADE : to Participate in the 41st Annual Canaccord Genuity Growth Conference
AQ
07/28ACCOLADE : 3 tips for a benefits strategy that keeps costs down
PU
07/26ACCOLADE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
07/22ACCOLADE : How Accolade keeps the annual healthcare cost trend flat
PU
07/13ACCOLADE : Baird Adjusts Accolade's Price Target to $58 From $54, Maintains Neut..
MT
More news
News in other languages on ACCOLADE, INC.
05/31PTA-NEWS : Philomaxcap AG: Verschlankung von Vorstand und Aufsichtsrat
More news
Analyst Recommendations on ACCOLADE, INC.
More recommendations
Chart ACCOLADE, INC.
Duration : Period :
Accolade, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCOLADE, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 44,99 $
Average target price 61,90 $
Spread / Average Target 37,6%
EPS Revisions
Managers and Directors
Rajeev Singh Chairman & Chief Executive Officer
Robert N. Cavanaugh President
Stephen H. Barnes Chief Financial Officer
Harish Naidu Chief Technology Officer
Shantanu Nundy Chief Medical Officer
Sector and Competitors